Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) FCF Margin (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed FCF Margin for 11 consecutive years, with 1215.1% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 23263.0% to 1215.1% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 142228.85% through Dec 2025, up 14229278.0% year-over-year, with the annual reading at 18489.75% for FY2025, 1842674.0% down from the prior year.
  • FCF Margin for Q4 2025 was 1215.1% at Cartesian Therapeutics, up from 5749.66% in the prior quarter.
  • The five-year high for FCF Margin was 1215.1% in Q4 2025, with the low at 5749.66% in Q2 2025.
  • Average FCF Margin over 5 years is 403.32%, with a median of 88.91% recorded in 2021.
  • The sharpest move saw FCF Margin skyrocketed 126402bps in 2024, then crashed -569940bps in 2025.
  • Over 5 years, FCF Margin stood at 106.02% in 2021, then skyrocketed by 32bps to 71.81% in 2022, then tumbled by -292bps to 281.54% in 2023, then soared by 449bps to 982.48% in 2024, then grew by 24bps to 1215.1% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 1215.1%, 5749.66%, and 2198.45% for Q4 2025, Q2 2025, and Q1 2025 respectively.